BPC-157 vs TB-500

For research purposes only. Neither BPC-157 nor TB-500 is approved for human therapeutic use by the MHRA, FDA, or any equivalent regulatory body. All content on this page reflects published scientific literature and is intended for researchers and laboratory professionals. Nothing in this article constitutes medical advice.

Overview: BPC-157 vs TB-500

BPC-157 and TB-500 are two of the most extensively studied synthetic research peptides in the field of tissue repair biology. Both have generated substantial preclinical evidence across wound healing, angiogenesis, and musculoskeletal research models. Both are legally available in the United Kingdom strictly for laboratory and in vitro research purposes. And both are prohibited under the World Anti-Doping Agency (WADA) 2026 Prohibited List under S2.

Despite these similarities, BPC-157 and TB-500 are fundamentally different molecules. They derive from entirely different biological sources, operate through distinct molecular mechanisms, and have different tissue affinities and research application profiles. Understanding the differences between BPC-157 and TB-500 is essential for researchers designing studies, evaluating the existing literature, or assessing which compound is most relevant to a specific area of investigation.

This article examines both peptides in depth — covering their molecular identity, mechanisms of action, preclinical evidence base, human research status, limitations of the current evidence, and regulatory position — using peer-reviewed studies from the UK, EU, and United States.

Molecular Identity: What Are They?

BPC-157

BPC-157 — Body Protection Compound 157 — is a synthetic 15-amino-acid pentadecapeptide with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It has a molecular weight of approximately 1,419 Da.

It is derived from a segment of a larger protective protein naturally occurring in human gastric juice, first isolated and characterised by Professor Predrag Šikirić and his team at the University of Zagreb, Croatia. Notably BPC-157 has no known endogenous counterpart in its isolated form — it is a sequence selected and synthesised from within a larger gastric protein, chosen for its biological stability and activity.

One of its most distinctive properties is its remarkable stability in human gastric juice, making it resistant to enzymatic degradation in ways that most peptides are not. It is available in lyophilised powder form and is water soluble.

TB-500

TB-500 is a synthetic research peptide derived from thymosin beta-4 (TB-4), a naturally occurring 43-amino-acid protein found in virtually every mammalian cell. TB-500 corresponds to the principal active region of TB-4 — specifically the actin-binding domain — and is significantly shorter than the full-length parent molecule.

A 2024 study published in the Journal of Chromatography B (Rahaman et al., 2024) added important complexity to our understanding of TB-500, demonstrating through UHPLC-Q-Exactive Orbitrap MS/MS analysis that TB-500 may function partly as a pro-drug, with its primary wound-healing activity attributed to a metabolite — specifically Ac-LKKTE — rather than the parent compound itself. This finding has significant implications for how TB-500 is characterised and studied going forward.

Mechanism of Action: How Do BPC-157 and TB-500 Work?

This is where the BPC-157 vs TB-500 comparison diverges most significantly. Despite both being studied for tissue repair applications, their molecular mechanisms are entirely different.

BPC-157: Nitric Oxide Signalling and Growth Factor Upregulation

BPC-157's primary mechanism operates through the nitric oxide (NO) pathway. A key study by Hsieh et al. (PubMed PMID: 27847966) demonstrated that BPC-157 enhances angiogenesis via the VEGFR2–Akt–eNOS signalling pathway — upregulating vascular endothelial growth factor receptor 2 (VEGFR2), which drives the formation of new blood vessels.

Additional mechanisms identified in the preclinical literature include:

• Upregulation of growth hormone receptors, particularly in tendon fibroblasts — providing a mechanistic basis for observed effects on connective tissue repair
• Activation of the FAK-paxillin pathway in tendon fibroblasts, stimulating collagen synthesis in animal models
• Modulation of the dopaminergic and GABAergic neurotransmitter systems — relevant to its studied neurological applications
• Cytoprotective effects on gastrointestinal mucosa, consistent with its origin from gastric juice
• Stabilisation of intestinal permeability, studied in the context of NSAID-induced gut toxicity (Park et al., 2020, Current Pharmaceutical Design, PMID: 32329394)

A 2025 study (PMID: 41155565) reported that BPC-157 has distinctive effects on nitric oxide levels and counteracts free radical formation, generating interest in potential neurological research applications including models relevant to Parkinson's disease and Alzheimer's disease.

TB-500: Actin Regulation and Cell Migration

TB-500's primary mechanism is fundamentally different — it operates through actin biology rather than NO signalling. Thymosin beta-4 is one of the most abundant actin-binding proteins in mammalian cells, functioning as a G-actin sequestering agent that regulates the equilibrium between globular (G-actin) and filamentous (F-actin) forms within cells.

By maintaining a reserve pool of G-actin monomers ready for rapid deployment, TB-4/TB-500 enables swift cytoskeletal reorganisation in response to injury signals — facilitating rapid cell migration into wounded areas. This actin-regulatory mechanism is the basis for TB-500's observed effects across multiple cell types including fibroblasts, endothelial cells, keratinocytes, and stem/progenitor cells.

After injury, thymosin beta-4 is released by platelets, macrophages, and many other cell types to protect cells and tissues from further damage and reduce apoptosis, inflammation, and microbial growth. It binds to actin and promotes cell migration, including the mobilisation, migration, and differentiation of stem/progenitor cells, which form new blood vessels and regenerate tissue.

A secondary but significant mechanism involves VEGF upregulation — providing an angiogenic effect that partially overlaps with BPC-157's mechanism, though through a different upstream pathway.

Preclinical Evidence: What Does the Research Show?

BPC-157

BPC-157 has accumulated one of the largest preclinical evidence bases of any research peptide, with approximately 200 peer-reviewed publications — though the concentration of authorship in that literature is a significant consideration discussed in the limitations section below.

Wound healing and tissue repair: A foundational study by Gwyer et al. (2019, Cell and Tissue Research, PMID: 30915550) reviewed BPC-157's role in accelerating musculoskeletal soft tissue healing, noting consistent findings across tendon, muscle, and ligament repair models. A January 2025 rat study (PMID: 39861766) demonstrated that oral BPC-157 successfully promoted muscle-to-bone reattachment in quadriceps injury models — a finding with significant implications given the practical advantages of oral over other administration routes.

Angiogenesis: Multiple studies have confirmed BPC-157's capacity to promote new blood vessel formation through VEGF upregulation and the VEGFR2–Akt–eNOS pathway, with particular relevance for tissues with poor native vascularisation such as tendons and cartilage.

Gastrointestinal protection: BPC-157 has a well-established preclinical record in gastrointestinal research, with studies examining its cytoprotective effects on gastric mucosa, its ability to counteract NSAID-induced gut toxicity, and its effects on intestinal permeability. This GI research profile is unmatched by TB-500, which has limited published GI-focused data.

Neuroscience: Preclinical models have examined BPC-157 in traumatic brain injury, dopaminergic system modulation, and models relevant to neurodegenerative conditions. The 2025 nitric oxide and free radical study (PMID: 41155565) added new mechanistic detail to this area.

TB-500

TB-500's preclinical evidence base is built predominantly around its parent molecule thymosin beta-4, with the distinction between TB-4 and TB-500 requiring careful attention when reviewing the literature.

Dermal wound healing: Thymosin beta-4 accelerated dermal healing of full-thickness punch wounds in various animal models, including normal rats and mice, steroid-treated rats, diabetic mice, and aged mice. The Treadwell et al. review (2012, Annals of the New York Academy of Sciences, PMID: 23050815) synthesised this evidence and noted consistent findings across multiple wound types and animal models.

Cardiac tissue: A landmark study by Bock-Marquette et al. published in Nature (2007, 432:466-472) demonstrated that thymosin beta-4 is cardioprotective after myocardial infarction in animal models, stimulating migration of cardiomyocytes and endothelial cells and promoting their survival. This cardiac evidence base is more developed for TB-500/TB-4 than for BPC-157.

Corneal and ocular tissue: Thymosin beta-4 has been studied under the clinical designation RGN-259 for corneal wound healing. A Phase III trial in neurotrophic keratopathy reported 60% complete corneal healing at four weeks compared to 12.5% for placebo — the strongest clinical evidence currently available for any thymosin beta-4 formulation.

Hair growth: A study published in PLoS ONE (Gao et al., 2015) demonstrated that thymosin beta-4 induces mouse hair growth — an area of ongoing research interest.

Human Research Status

BPC-157

Until recently published human data for BPC-157 was extremely limited. This changed in 2025 with the publication of a landmark pilot study.

Lee and Burgess (2025) published the first peer-reviewed study of intravenous BPC-157 administration in humans in Alternative Therapies in Health and Medicine (PMID: 40131143). Intravenous infusion of up to 20 mg of BPC-157 in 2 healthy adults showed no adverse effects and was well-tolerated. The infusions of BPC-157 resulted in no measurable effects on the tested biomarkers of the heart, liver, kidneys, thyroid, or blood glucose levels.

This represents a meaningful step forward — but important context is required. This was an IRB-approved pilot safety study involving only two participants, with no control group and no efficacy endpoints. It demonstrates preliminary tolerability, not clinical efficacy. As of 2026, no randomised controlled trial of BPC-157 in humans has been published for any indication.

Two additional small human studies have been conducted: a retrospective study of intra-articular injection for knee pain (Lee and Padgett, 2021) reporting that 14 of 16 patients reported significant pain relief; and a pilot study of BPC-157 in patients with interstitial cystitis (Lee et al., 2024, PMID: 39325560) reporting 80-100% symptom resolution in 12 patients. Across all three studies approximately 30 participants have received BPC-157 in human settings with no adverse events reported. These are small, largely uncontrolled studies — they cannot establish efficacy and should be interpreted with appropriate caution.

TB-500

TB-500's human data is more developed than BPC-157's, though it derives from trials using the full-length thymosin beta-4 molecule rather than the synthetic TB-500 fragment specifically.

In two Phase 2 clinical trials of stasis and pressure ulcers, thymosin beta-4 was found to accelerate healing by almost a month in patients who did heal. The cardiac pilot study by Zhu et al. (2016, Cytotherapy, PMID: 27288307) examined thymosin beta-4 pre-treated endothelial progenitor cell transplantation in patients with acute myocardial infarction, noting preliminary safety and efficacy signals.

The RGN-259 ophthalmic formulation has progressed furthest in clinical development, completing Phase 2 trials for dry eye disease and a Phase 3 trial for neurotrophic keratopathy. No regulatory approval has been granted for any indication as of 2026.

Researchers must note that findings from TB-4 trials do not automatically transfer to TB-500, which is a shorter synthetic fragment. The two are related but chemically distinct.

Limitations of the Current Evidence Base

Researchers evaluating the BPC-157 vs TB-500 literature should be aware of several important limitations that affect how findings should be interpreted.

BPC-157 — authorship concentration: Nearly all of the roughly 200 BPC-157 studies listed on PubMed include either Sikiric or his colleague Sven Seiwerth as a main author. A Polish review team flagged this concentration as a risk for confirmation bias. The McGuire et al. scoping review published in December 2025 noted that all published studies report positive effects, raising further questions about publication bias. Independent replication of the Zagreb group's findings remains limited — an important consideration when assessing the strength of the BPC-157 evidence base.

Additionally, Sikiric is named on BPC-157 patents dating to 1989 and is listed as CEO of Diagen, a company selling a patented version of the compound. These conflicts were not disclosed in his published papers. Researchers should factor these undisclosed conflicts into their assessment of the literature.

TB-500 — TB-4 vs TB-500 distinction: The majority of clinical and advanced preclinical data for TB-500 uses the full-length thymosin beta-4 molecule, not the synthetic TB-500 fragment. The 2024 Rahaman et al. finding that TB-500 may act as a pro-drug further complicates direct comparison with the TB-4 literature.

Animal to human translation: The overwhelming majority of evidence for both compounds comes from animal models — primarily rodent studies conducted under controlled laboratory conditions. Animal findings do not automatically translate to human outcomes. As of 2026, neither compound has completed a randomised controlled trial in humans for any indication.

Comparing Research Applications

The Wolverine Stack: Researching BPC-157 and TB-500 Together

Given their mechanistically complementary profiles, BPC-157 and TB-500 are frequently studied in combination in the research literature. BPC-157 primarily influences growth factor receptor signalling and NO modulation, while TB-500 acts through actin dynamics and endothelial cell migration. This complementarity makes the combination scientifically compelling.

The scientific rationale is that the two compounds address different nodes of the tissue repair cascade simultaneously — BPC-157 driving vascular and connective tissue responses through NO and VEGF signalling, TB-500 facilitating cell migration and cytoskeletal reorganisation through actin regulation. Whether this produces additive or synergistic effects in experimental models remains an active area of investigation.

Researchers studying all three compounds together may find the GLOW Stack relevant for combined research applications.

For research purposes only: Velyx Research Ltd supplies BPC-157 5mg and TB-500 5mg individually and as the Wolverine Stack at >99% purity with independent Janoshik Certificates of Analysis. All products are for laboratory and in vitro research use only and are not intended for human or animal administration.

Regulatory and Safety Context

UK and MHRA

Neither BPC-157 nor TB-500 is licensed or approved for any human use by the MHRA. Both are available in the UK strictly as research chemicals for laboratory and in vitro research purposes only. They are not controlled substances under UK drug law but must not be marketed with therapeutic claims. For a full overview of the UK regulatory framework for research peptides, see our guide: [Are Peptides Legal in the UK? A Researcher's Complete Guide (2026)].

US, FDA, and the 2026 Regulatory Landscape

The FDA has not approved either compound for any therapeutic indication. BPC-157 was classified as a Category 2 bulk drug substance in 2023, meaning it was not permitted for use in compounded preparations. TB-500/thymosin beta-4 remains an investigational compound without approved drug status in the United States.

Importantly, the US regulatory position shifted in early 2026. On February 27, 2026, HHS Secretary RFK Jr. announced that roughly 14 of 19 restricted peptides would be re-categorised such that the FDA would permit them to be compounded once again. However as of now, no formal FDA rule has actually changed — the actual process of rule-making, supply chain readiness, and possibly public comment will take months at a minimum. An FDA advisory committee meeting has been announced for summer 2026 to review whether several peptides should be added back to the compounding available list. Researchers and institutions should monitor developments closely — the regulatory position in the US remains in active flux.

WADA

Both BPC-157 and TB-500 are prohibited under the WADA 2026 Prohibited List, classified under S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics). This prohibition applies both in and out of competition. Researchers working in sport science contexts should be aware of this classification as a separate governance consideration from UK civil and criminal law.

Safety Profile

Preclinical safety data for both compounds shows generally good tolerability in animal models with no major toxicity identified. The 2025 Lee and Burgess pilot study represents the first formal human safety data for BPC-157 administered intravenously, with two participants tolerating doses up to 20mg without adverse effects. Long-term human safety data for both compounds remains unavailable. Researchers should approach all experimental compounds with appropriate institutional oversight and caution.

Summary: Key Differences Between BPC-157 and TB-500

Origin: BPC-157 derives from human gastric juice protein; TB-500 derives from the actin-binding domain of thymosin beta-4, a naturally occurring mammalian protein.

Mechanism: BPC-157 operates primarily through nitric oxide signalling and growth factor receptor upregulation; TB-500 operates primarily through actin regulation and cell migration facilitation.

Molecular size: BPC-157 is a 15-amino-acid peptide (1,419 Da); TB-500 is a shorter synthetic fragment of a 43-amino-acid parent molecule.

GI research: BPC-157 has a substantially stronger gastrointestinal research profile — consistent with its gastric origins. TB-500 has limited GI data.

Cardiac research: TB-500/thymosin beta-4 has a more developed cardiac evidence base including the landmark 2007 Nature study.

Human data: Both are in early stages. BPC-157 has three small pilot studies published 2021–2025. TB-500's parent molecule has completed Phase 2 trials in wound healing and cardiac applications.

Neurological research: BPC-157 has the stronger and more developed neurological evidence base.

Evidence limitations: BPC-157's evidence base is heavily concentrated in a single research group with undisclosed conflicts of interest. TB-500's clinical data derives from the parent TB-4 molecule rather than the synthetic fragment.

Frequently Asked Questions: BPC-157 vs TB-500

What is the main difference between BPC-157 and TB-500? The primary difference between BPC-157 and TB-500 is their mechanism of action. BPC-157 operates through nitric oxide signalling and VEGF upregulation, while TB-500 operates through actin regulation and cell migration facilitation. They target different nodes of the tissue repair cascade through entirely distinct molecular pathways.

Can you use BPC-157 and TB-500 together in research? Yes — BPC-157 and TB-500 are frequently studied together in preclinical research, referred to informally as the Wolverine Stack. Their mechanistic complementarity — BPC-157 targeting vascular signalling, TB-500 targeting cellular migration — makes their combination a subject of active scientific investigation into potential additive or synergistic effects.

Which is better — BPC-157 or TB-500? Neither is universally better. They serve different research purposes. BPC-157 has the stronger gastrointestinal and neurological research profile. TB-500 has the more developed cardiac evidence base and broader systemic cell migration mechanism. The choice depends entirely on the research application being studied.

What is the Wolverine Stack? The Wolverine Stack is the informal term used in research communities for the combination of BPC-157 and TB-500. The name reflects the compounds' complementary tissue repair mechanisms. Both are available from Velyx Research Ltd for laboratory research purposes only.

Are BPC-157 and TB-500 legal in the UK? Yes — both are legal to purchase and possess in the UK for laboratory research purposes only. Neither is a controlled substance under UK law. Neither is approved by the MHRA for human use. For a full explanation of the UK regulatory framework see our article: Are Peptides Legal in the UK? A Researcher's Complete Guide (2026).

Is TB-500 the same as thymosin beta-4? No — they are related but distinct. Thymosin beta-4 (TB-4) is the full 43-amino-acid naturally occurring protein. TB-500 is a shorter synthetic fragment corresponding to TB-4's active actin-binding region. Research findings from TB-4 trials do not automatically apply to TB-500 and vice versa.

What happened to BPC-157 and TB-500 regulation in the US in 2026? In February 2026, HHS Secretary RFK Jr. announced that approximately 14 previously restricted peptides — potentially including BPC-157 — would be re-categorised to permit compounding once again. However no formal FDA rule change has taken effect as of May 2026. The regulatory position in the US remains in active flux and researchers should monitor developments closely.

References

BPC-157 in humans: A pilot study. Alternative Therapies in Health and Medicine, 31(5), 20–24. PubMed PMID: 40131143

Lee, E., Walker, C., and Ayadi, B. (2024). Effect of BPC-157 on symptoms in patients with interstitial cystitis: A pilot study. Alternative Therapies in Health and Medicine, 30(10), 12–17. PubMed PMID: 39325560

Lee, E., and Padgett, B. (2021). Intra-articular injection of BPC-157 for multiple types of knee pain. Alternative Therapies in Health and Medicine, 27(4), 8–13.

McGuire, F.P., Martinez, R., Lenz, A., Skinner, L., and Cushman, D.M. (2025). Regeneration or risk? A narrative review of BPC-157 for musculoskeletal healing. Current Reviews in Musculoskeletal Medicine, 18(12), 611–619. doi: 10.1007/s12178-025-09990-7. PubMed PMID: 40789979

Gwyer, D., Wragg, N.M., and Wilson, S.L. (2019). Gastric pentadecapeptide body protection compound BPC-157 and its role in accelerating musculoskeletal soft tissue healing. Cell and Tissue Research, 377(2), 153–159. PubMed PMID: 30915550

Park, J.M., Lee, H.J., Sikiric, P., and Hahm, K.B. (2020). BPC-157 rescued NSAID-cytotoxicity via stabilising intestinal permeability and enhancing cytoprotection. Current Pharmaceutical Design, 26(25), 2971–2981. PubMed PMID: 32329394

Hsieh, M.J., et al. (2017). BPC-157 enhances angiogenesis via VEGFR2–Akt–eNOS pathway and promotes post-ischaemic recovery. PubMed PMID: 27847966

Rahaman, K.A., Muresan, A.R., Min, H., Son, J., Han, H., Kang, M., and Kwon, O. (2024). Simultaneous quantification of TB-500 and its metabolites in in-vitro experiments and rats by UHPLC-Q-Exactive Orbitrap MS/MS and their screening by wound healing activities in-vitro. Journal of Chromatography B, 1235, 124033.

Goldstein, A.L., Hannappel, E., Sosne, G., and Kleinman, H.K. (2012). Thymosin beta-4: a multi-functional regenerative peptide. Basic properties and clinical applications. Expert Opinion on Biological Therapy, 12(1), 37–51. PubMed PMID: 22074294

Treadwell, T., Kleinman, H.K., Crockford, D., Hardy, M.A., Guarnera, G.T., and Goldstein, A.L. (2012). The regenerative peptide thymosin beta-4 accelerates the rate of dermal healing in preclinical animal models and in patients. Annals of the New York Academy of Sciences, 1270, 37–44. PubMed PMID: 23050815

Bock-Marquette, I., Saxena, A., White, M.D., DiMaio, J.M., and Srivastava, D. (2004). Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair. Nature, 432(7016), 466–472. doi: 10.1038/nature03000. PubMed PMID: 15549101

Zhu, J., Song, J., Yu, L., Zheng, H., Zhou, B., Weng, S., and Fu, G. (2016). Safety and efficacy of autologous thymosin beta-4 pre-treated endothelial progenitor cell transplantation in patients with acute ST-segment elevation myocardial infarction: a pilot study. Cytotherapy, 18(8), 1037–1042. PubMed PMID: 27288307

Gao, X., Liang, H., Hou, F., Zhang, Z., Nuo, M., Guo, X., and Liu, D. (2015). Thymosin beta-4 induces mouse hair growth. PLoS ONE, 10(6), e0130040.

World Anti-Doping Agency (WADA). (2026). 2026 Prohibited List: International Standard. Available at: wada-ama.org

Medicines and Healthcare products Regulatory Agency (MHRA). Human Medicines Regulations 2012. UK Government. Available at: legislation.gov.uk

Velyx Research Ltd supplies research-grade peptides to qualified researchers in the United Kingdom. All products are for laboratory and in vitro research use only and are not intended for human or animal administration. Company No. 03697395.

This article is for informational and educational purposes only and does not constitute medical advice. Velyx Research Ltd is not a medical or pharmaceutical company and does not provide clinical guidance.